Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus.
about
Calprotectin in rheumatic diseases: a review.Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs.Nutritional Immunity: S100 Proteins at the Host-Pathogen Interface.Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for interventionS100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery StudyPlatelet-Derived S100A8/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus.Calprotectin in rheumatic diseases.Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus.The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study.Evaluation of Serum S100A8/S100A9 Levels in Patients with Autoimmune Thyroid Diseases.Stress-induced release of the S100A8/A9 alarmin is elevated in coronary artery disease patients with impaired cortisol response.S100A12 concentrations and myeloperoxidase activities are increased in the intestinal mucosa of dogs with chronic enteropathies.
P2860
Q34549912-DF55A6A7-7487-40D2-A9D4-DD0F8E95036AQ35737906-28505711-045D-4D6C-BC18-2575D925ED5DQ35775425-47AF627A-AD4C-4C5F-9178-3EF0B4892382Q35905318-B26844F9-A864-4FCB-BE64-7278EA188AEEQ35998510-18D842DD-1060-4BEE-8011-B4A2D88BFCC8Q36631781-9AF2DA3C-E894-4F4E-B938-572816C0382DQ37436729-D8DC3C09-6162-47B8-8BD3-333D0A213FFEQ37541229-1644C858-010C-4C07-9E3B-8C2FB1DA9A67Q38899360-A24BC130-E042-4256-9051-721C5E135797Q39022858-4C13B44C-76E4-48C9-99FE-7E5FCB1FDBE1Q39095935-713A9E80-DD15-41BC-8EEB-DB1BC35B9222Q39608198-D6BC6F55-89D5-4AD0-83FB-11B191D91A60Q41253670-06063C2F-9502-47B7-ADCC-DF8E557E1B78Q41383822-1AA573A9-832A-4C79-B0B2-7B626D0A6AFBQ47163914-6A45B2C6-6ED0-44E0-9805-BB79C6F2C1CCQ55434420-F283E9A0-A4EB-4C05-9FAC-2DC548C8F4CD
P2860
Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Increased serum levels of S100 ...... systemic lupus erythematosus.
@en
Increased serum levels of S100 ...... systemic lupus erythematosus.
@nl
type
label
Increased serum levels of S100 ...... systemic lupus erythematosus.
@en
Increased serum levels of S100 ...... systemic lupus erythematosus.
@nl
prefLabel
Increased serum levels of S100 ...... systemic lupus erythematosus.
@en
Increased serum levels of S100 ...... systemic lupus erythematosus.
@nl
P2093
P2860
P356
P1433
P1476
Increased serum levels of S100 ...... e systemic lupus erythematosus
@en
P2093
Anders A Bengtsson
Andreas Jönsen
Birgitta Gullstrand
Fredrik Ivars
Gunnar Sturfelt
Helena Tydén
Lennart Truedsson
Tomas Leanderson
P2860
P304
P356
10.1093/RHEUMATOLOGY/KET263
P577
2013-08-13T00:00:00Z